Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor used for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease. Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil.
- Mechanism
- Curator reviewed · 4 references
Tenofovir alafenamide presents 91% lower plasma concentration with an intracellular presence of about 20-fold higher when compared to tenofovir disoproxil. This is due to its prolonged systemic exposure and its higher intracellular accumulation of the active metabolite tenofovir diphosphate.
Tenofovir alafenamide accumulates more in peripheral blood mononuclear cells compared to red blood cells.
Once activated, tenofovir acts with different mechanisms including the inhibition of viral polymerase, causing chain termination and the inhibition of viral synthesis. To know more about the specific mechanism of action of the active form, please visit the drug entry of tenofovir.
- Primary indication
- Tenofovir alafenamide is indicated for the treatment of hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.Curator reviewed · 9 structured indications
- Formula / weight
- C21H29N6O5P · 476.474 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2015 · European Union, 2016
- Code names
- GS-7340 · GS-7340-03
- Brand names
Resolves to
LDEKQSIMHVQZJK-CAQYMETFSA-NSMILESCC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Tenofovir alafenamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account